Merck & Co. Inc.MRK
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NYSE · United States · merck.com
Merck & Co., Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and markets a broad range of innovative medicines, vaccines, and animal health products. The company's key products include oncology treatments such as Keytruda (pembrolizumab), vaccines including Gardasil, and treatments for infectious diseases and diabetes. Merck is headquartered in Rahway, New Jersey, United States.
Key ratios
Operating cash flow growth
7.7%TTM
2025
-23.3%2024
65.1%2023
-31.9%
EPS growth
-80.4%TTM
2025
8.0%2024
4714.3%2023
-97.6%
FCF / Sales
24.1%TTM
2025
19.0%2024
28.2%2023
15.2%
Net margin
4.8%TTM
2025
28.1%2024
26.7%2023
0.6%
ROA
11.9%TTM
2025
12.0%2024
13.9%2023
9.3%
ROE
7.0%TTM
2025
36.9%2024
40.8%2023
0.9%
Revenue growth
4.6%TTM
2025
1.3%2024
6.7%2023
1.4%
Recent news
Health Canada Approves KEYTRUDA® for Treatment of Adult Patients with Muscle Invasive Bladder Cancer Ineligible for Cisplatin Chemotherapy in Combination with Enfortumab Vedotin
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
Track MRK in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer